News

Although ‘lean type 2 diabetes’ is not uncommon, clinicians must first exclude other causes including autoimmune, monogenic, ...
In today's dynamic and volatile market terrain, investors are increasingly drawn to opportunities that promise robust growth ...
Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...
In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...
Eli Lilly’s stock closed at $786.92, marking a 1.19% gain, outpacing the broader market. Despite a 3.66% drop in the past ...
Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...
Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...
Shares of Eli Lilly & Co. LLY rose 1.19% to $786.92 Wednesday, on what proved to be an all-around great trading session for ...
Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...
The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...
A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...
The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...